StockWatch
·

Parmax Pharma Ltd Q4 FY25 Results

PARMAXQ4 FY25 Results
Filing
MetricValue ( Cr)vs Q3 FY25
Revenue4.8323.2%
Total Income4.7324.9%
Expenditure5.4518.5%
PBT-1.80354.7%
Net Profit-1.49278.5%
OPM-33.93%19.24pp
NPM-31.62%25.35pp
EPS4.00480.9%
View full financials

Informational and educational content only. Not investment advice.